Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.
Correale P, Saladino RE, Giannarelli D, Giannicola R, Agostino R, Staropoli N, Strangio A, Del Giudice T, Nardone V, Altomonte M, Pastina P, Tini P, Falzea AC, Imbesi N, Arcati V, Romeo G, Caracciolo D, Luce A, Caraglia M, Giordano A, Pirtoli L, Necas A, Amler E, Barbieri V, Tassone P, Tagliaferri P. Correale P, et al. Among authors: barbieri v. J Immunother Cancer. 2020 Jun;8(1):e000733. doi: 10.1136/jitc-2020-000733. J Immunother Cancer. 2020. PMID: 32554614 Free PMC article.
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.
Botta C, Barbieri V, Ciliberto D, Rossi A, Rocco D, Addeo R, Staropoli N, Pastina P, Marvaso G, Martellucci I, Guglielmo A, Pirtoli L, Sperlongano P, Gridelli C, Caraglia M, Tassone P, Tagliaferri P, Correale P. Botta C, et al. Among authors: barbieri v. Cancer Biol Ther. 2013 Jun;14(6):469-75. doi: 10.4161/cbt.24425. Cancer Biol Ther. 2013. PMID: 23760488 Free PMC article.
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis.
Nardone V, Giannicola R, Giannarelli D, Saladino RE, Azzarello D, Romeo C, Bianco G, Rizzo MR, Di Meo I, Nesci A, Pastina P, Falzea AC, Caracciolo D, Reginelli A, Caraglia M, Luce A, Mutti L, Giordano A, Cappabianca S, Pirtoli L, Barbieri V, Tassone P, Tagliaferri P, Correale P. Nardone V, et al. Among authors: barbieri v. Life (Basel). 2021 Nov 15;11(11):1235. doi: 10.3390/life11111235. Life (Basel). 2021. PMID: 34833111 Free PMC article.
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P. Arbitrio M, et al. Among authors: barbieri v. Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25. Cancer Chemother Pharmacol. 2016. PMID: 26607259
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.
Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Nardone V, Monoriti M, Calabrese G, Tripepi G, Pirtoli L, Tassone P, Tagliaferri P, Correale P. Giannicola R, et al. Among authors: barbieri v. Mol Clin Oncol. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16. Mol Clin Oncol. 2019. PMID: 31289683 Free PMC article.
Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab.
Nardone V, Tini P, Pastina P, Botta C, Reginelli A, Carbone SF, Giannicola R, Calabrese G, Tebala C, Guida C, Giudice A, Barbieri V, Tassone P, Tagliaferri P, Cappabianca S, Capasso R, Luce A, Caraglia M, Mazzei MA, Pirtoli L, Correale P. Nardone V, et al. Among authors: barbieri v. Oncol Lett. 2020 Feb;19(2):1559-1566. doi: 10.3892/ol.2019.11220. Epub 2019 Dec 16. Oncol Lett. 2020. PMID: 31966081 Free PMC article.
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
Siciliano MA, Caridà G, Ciliberto D, d'Apolito M, Pelaia C, Caracciolo D, Riillo C, Correale P, Galvano A, Russo A, Barbieri V, Tassone P, Tagliaferri P. Siciliano MA, et al. Among authors: barbieri v. ESMO Open. 2022 Jun;7(3):100465. doi: 10.1016/j.esmoop.2022.100465. Epub 2022 Apr 12. ESMO Open. 2022. PMID: 35427835 Free PMC article.
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report.
d'Apolito M, Spagnuolo R, Siciliano MA, Barbieri V, Cosco C, Fiorillo L, Cuomo O, Zuccalà V, Correale P, Pensabene L, Rossi M, Doldo P, Tassone P, Tagliaferri P. d'Apolito M, et al. Among authors: barbieri v. Ther Adv Chronic Dis. 2022 Jan 13;13:20406223211063024. doi: 10.1177/20406223211063024. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35070249 Free PMC article.
187 results